Peapod Lane Capital LLC Acquires Shares of 642,193 Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Peapod Lane Capital LLC acquired a new position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 642,193 shares of the company's stock, valued at approximately $867,000. Peapod Lane Capital LLC owned about 1.05% of Pliant Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Aquatic Capital Management LLC raised its stake in Pliant Therapeutics by 1,299.0% during the 4th quarter. Aquatic Capital Management LLC now owns 5,596 shares of the company's stock valued at $74,000 after buying an additional 5,196 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Pliant Therapeutics during the 4th quarter valued at about $99,000. KLP Kapitalforvaltning AS bought a new position in shares of Pliant Therapeutics in the 4th quarter worth approximately $108,000. Corton Capital Inc. purchased a new position in shares of Pliant Therapeutics in the fourth quarter worth approximately $138,000. Finally, Atria Investments Inc boosted its holdings in shares of Pliant Therapeutics by 18.1% in the fourth quarter. Atria Investments Inc now owns 11,821 shares of the company's stock worth $156,000 after buying an additional 1,812 shares during the last quarter. 97.30% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 18th. Twelve equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $13.31.

Pliant Therapeutics Stock Performance

Shares of PLRX traded up $0.01 during mid-day trading on Friday, reaching $1.41. The stock had a trading volume of 581,363 shares, compared to its average volume of 1,197,067. The business has a fifty day moving average of $1.37 and a 200 day moving average of $3.84. The firm has a market cap of $86.56 million, a price-to-earnings ratio of -0.39 and a beta of 1.30. Pliant Therapeutics, Inc. has a 12 month low of $1.10 and a 12 month high of $16.10.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.